La Jolla Pharmaceutical (NDAQ:LJPC) Rating Maintained
In an analyst report revealed on Friday, 22 December, La Jolla Pharmaceutical (NDAQ:LJPC) stock Buy was maintained by Analysts at Suntrust Robinson. They currently have a $65.00 target price on the stock. Suntrust Robinson’s target price indicates a potential upside of 268.90 % from the company’s close price.
NDAQ:LJPC is right now trading 0.00% lower at $0.00 as of 7:58 AM New York time. La Jolla Pharmaceutical’s stock is 0% over the last 200 days. It has underperformed the S&P500 Index, which has gained 6.00% over the same time.
According to data compiled by Thomson Reuters, La Jolla Pharmaceutical (NDAQ:LJPC)’s stock is covered by 5 equity analysts across the Street, with 0 analysts giving it a Sell rating, 5 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $42, which reflects an upside potential of ∞% over the current price.
Tang Capital Management Llc had the biggest stake with ownership of 3.19 million shares as of q2 2015 for 31.49% of the fund portfolio. Rtw Investments Llc is another very bullish institutional investor who is possessing 1.17 million shares of La Jolla Pharmaceutical or 8.41% of their fund portfolio. Furthermore, Broadfin Capital Llc have 3.09% of their fund portfolio invested in the company for 1.45 million shares. The New York-based fund Perceptive Advisors Llc disclosed it had bought so far a stake worth about 2.03% of the institutional investor’s stock portfolio in La Jolla Pharmaceutical. The Connecticut-based fund P.A.W. Capital Corp is also positive about the stock, possessing 1.32 million shares or 0.9% of their fund portfolio.
La Jolla Pharmaceutical (NDAQ:LJPC) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. La Jolla Pharmaceutical has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest La Jolla Pharmaceutical (NDAQ:LJPC) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post 268.90 % to Target, Suntrust Robinson Reaffirms Buy Rating for La Jolla Pharmaceutical (NDAQ:LJPC) Stock appeared first on Octafinance.